Abstract 191P
Background
Esophageal cancer is a major problem in India, but under-reported many times. The patients usually present in late stages as the symptoms are non-specific. The management of these cancers has improved significantly largely due to the multidisciplinary treatment options that have dramatically improved over the last decade. The aim is to analyze the clinico-demographic profiles and survival outcomes of patients with esophageal malignancy at our institute where most patients are from rural backgrounds in India.
Methods
Data of non-metastatic carcinoma esophagus patients were taken from Medical records from January 2020 to December 2023. Clinico-demographic data and survival patterns with multimodality approaches were analyzed.
Results
47 patients were included in our study. The mean age at presentation is 55 years. Male to female ratio is 2:3. 18 (38.3%) were smokers &12 (25.5%) were alcoholics. The commonest site is the Middle thoracic esophagus in 22 patients (46.8%), 5 (31.9%) had a lower third. Squamous cell carcinoma is the most common histology (82%). Stage 2 is the most common stage of presentation in 22 (46.8%) followed by stage 3 (36.2%). 20 received Neo Adjuvant Chemo Radiotherapy (NACRT), 13 (65%) received paclitaxel+ carboplatin (weekly), 7(35%) received CAPEOX regimen along with radiation (41.4 to 45 Gray). Of these, only 8(40%) underwent surgery, while 12 (60%) could not. 5 (62.5%), who underwent surgery achieved pathological complete response. 24 received defenitive CRT with 14(58.3%) achieving complete response and 10(41.6%) having partial response. 3 patients defaulted without treatment. The median overall survival of the analyzed population is 10.5 months. In a subset analysis, the survival of patients who underwent surgery was 12 months, and without surgery was 8 months.
Conclusions
Outcomes of esophageal cancer despite the advances in the multimodality treatment are still dismal, our study also shows that patients who are not able to undergo surgery after NACRT has lowest survival. we need to critically analyse the reasons for not able to perform radical surgery despite NACRT in order to improve survival rates, where use of immunotherapy is still not feasible.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
V. R. Matta.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.